Bloomberg recently interviewed author and stem-cell "industry" specialist Robin Young for his views. "Biotech needs stem cell research," he says, and the first stem cell-based treatments for auto-immune diseases, may be coming through the FDA cycle in about two years, he says.
Bloomberg - (BLOOM)
Mar. 23, 2007. 12:59 PM EST